Defining the best therapeutic strategy and optimal systemic therapy in patients with endocrine receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC) is often a complex decision. This evidence concerns the gene ERBB2 and breast cancer.